-$0.11 Earnings Per Share Expected for DelMar Pharmaceuticals Inc (DMPI) This Quarter

Wall Street analysts expect that DelMar Pharmaceuticals Inc (NASDAQ:DMPI) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.20) during the same quarter last year, which would indicate a positive year-over-year growth rate of 45%. The business is scheduled to report its next quarterly earnings report on Wednesday, September 26th.

On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.54) per share for the current year. For the next financial year, analysts forecast that the company will post earnings of ($0.30) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow DelMar Pharmaceuticals.

DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its earnings results on Tuesday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03).

A number of analysts have weighed in on the stock. HC Wainwright set a $12.00 target price on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 23rd. ValuEngine raised shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd.

Shares of DelMar Pharmaceuticals traded down $0.05, reaching $0.70, during midday trading on Friday, according to MarketBeat. 528,560 shares of the company were exchanged, compared to its average volume of 206,171. The stock has a market cap of $16.50 million, a PE ratio of -0.95 and a beta of 1.45. DelMar Pharmaceuticals has a one year low of $0.65 and a one year high of $2.84.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply